Targeting the protein subcomplex in pancreatic cancer stem cells with a KMT2A-WDR5 inhibitor attenuated their self-renewal capacity, cell viability, and in vivo tumorigenicity.
[Nature Communications]
Home Newsletters Cancer Stem Cell News KMT2A Associates with PHF5A-PHF14-HMG20A-RAI1 Subcomplex in Pancreatic Cancer Stem Cells and Epigenetically...
